ATAD1 and malaria: Blood-stage malaria vaccine development has classically focused on recombinant protein-in-adjuvant formulations (Genton and Reed, 2007); however, we have described the use of replication-defective viral vaccine vectors expressing the malaria antigen merozoite surface protein-1 (MSP-1) as a promising alternative vaccination strategy (Draper et al., 2008).